Home > News > 1/Gap junction modulation is a major determinantof the mechanism and organisation of ventricularfibrillation and a potential therapeutic target
Arrhythmia
Read Time: 2 mins

1/Gap junction modulation is a major determinantof the mechanism and organisation of ventricularfibrillation and a potential therapeutic target

Published Online: September 27th 2008 European Journal of Arrhythmia & Electrophysiology. 2019;5(Suppl. 1):abstr1
Authors: B S Handa (Presenting Author) - Imperial College London, London, UK; X Li - Imperial College London, London, UK; C Roney - Imperial College London, London, UK; D Pitcher - Imperial College London, London, UK; R A Chowdhury - Imperial College London, London, UK; N S Peters - Imperial College London, London, UK; F S Ng - Imperial College London, London, UK
Quick Links:
Article
Article Information
Article:

Background: Mechanisms that maintain ventricular fibrillation (VF) remain debated. There are both clinical and experimental data to support the existence of rotational drivers (RDs), though other conflicting studies have not demonstrated such drivers and suggested that VF is the result of disorganised myocardial activation. Abnormal electrical coupling between cardiomyocytes through gap junctions (GJ) has been considered an important factor in initiation and maintenance of VF and pre-treatment with GJ couplers has been shown to reduce VF inducibility.

Purpose: We hypothesised that the underlying mechanism of VF is determined by the degree of GJ coupling, and that changes in GJ coupling can shift or modify the predominant mechanism of fibrillation along the spectrum between disorganised activity and organised drivers. We postulated that increased organisation of VF is critical to its termination.

Methods: Thirty Sprague-Dawley rat hearts were explanted, perfused ex vivo and VF induced with burst pacing and 30 μM pinacidil. Optical mapping of transmembrane potential was performed at baseline and the effects of GJ coupling on VF dynamics were studied in an acute VF model by perfusing with increasing concentrations of a GJ uncoupler; carbenoxolone (0–50 µM, CBX, n=10) or a GJ coupling-enhancer; rotigaptide (0–80 nM, RTG, n=10). A chronic diffuse fibrosis model (n=10) was generated with 4 weeks of in vivo angiotensin infusion (500 nm/kg/min). Fibrillation dynamics were quantified using phase analysis, phase singularity (PS) tracking and our novel method of global fibrillation organisation quantification, frequency dominance index (FDI), which is defined as the power ratio of highest amplitude dominant frequency in the frequency spectrum.

Results: RTG increased average rotations per RD (Baseline: 2.86 ± 0.10 versus 80 nM: 5.66 ± 0.43, p<0.001) whilst CBX caused a reduction (Baseline: 3.77 ± 0.39 versus 50 µM: 0.26 ± 0.26, p<0.001). Maximum rotations for a RD increased with RTG (5.4 ± 0.45 versus 48.20 ± 12.32, p<0.001) and decreased with CBX (8.0 ± 1.3 versus 0.3 ± 0.3, p<0.001). Proportion of time PSs were detected in VF increased with RTG
(0.44 ± 0.06 versus 0.93 ± 0.02, p<0.001) and decreased with CBX
(0.61 ± 0.9 versus 0.03 ± 0.02, p<0.001). RTG reduced meander of longest duration RD (20.6 ± 1.68 versus 11.51 ± 0.77 pixels, p<0.001) for PS >5 rotations. FDI increased with RTG (0.53 ± 0.04 versus 0.78 ± 0.3, p<0.001) and decreased with CBX (0.60 ± 0.05 versus 0.17 ± 0.03, p<0.001). In the diffuse fibrosis group, in comparison to baseline RTG 80 nM increased FDI (0.35 versus 0.65, p<0.001) and terminated VF in 40% of hearts.

Conclusion: The degree of GJ coupling is a key determinant of the underlying mechanism of VF. RTG organised fibrillation and stabilised RDs in a concentration-dependent manner whilst CBX disorganised VF. Enhancing GJ coupling with RTG in diseased hearts with fibrosis can terminate VF. GJ coupling may be a potential therapeutic target in VF.

Article Information:

Further Resources

Share this Article
Related Content In Arrhythmia
Arrhythmia
43/Cardiac tamponade as a complication of transseptal puncture: associations and operatordependent variables during left atrial ablation at Barts Heart Centre
E Maclean (Presenting Author) - St Bartholomew’s Hospital, London; K Mahtani - St Bartholomew’s Hospital, London; C Butcher - St Bartholomew’s Hospital, London; N Ahluwalia - St Bartholomew’s Hospital, London; M Finlay - St Bartholomew’s Hospital, London; S Honarbakhsh - St Bartholomew’s Hospital, London; A Creta - St Bartholomew’s Hospital, London; A Chow - St Bartholomew’s Hospital, London; V Sawhney - St Bartholomew’s Hospital, London; V Ezzat - St Bartholomew’s Hospital, London; MJ Earley - St Bartholomew’s Hospital, London; M Dhinoja - St Bartholomew’s Hospital, London; S Sporton - St Bartholomew’s Hospital, London; MD Lowe - St Bartholomew’s Hospital, London; PD Lambiase - St Bartholomew’s Hospital, London; F Khan - St Bartholomew’s Hospital, London; SY Ahsan - St Bartholomew’s Hospital, London; RJ Hunter - St Bartholomew’s Hospital, London; RJ Schilling - St Bartholomew’s Hospital, London; O Sega - St Bartholomew’s Hospital, London Read Time: 2 mins

European Journal of Arrhythmia & Electrophysiology. 2021;7(Suppl. 1):abstr43

Introduction: Cardiac tamponade is a high morbidity complication of transseptal puncture (TSP). We examined the incidence and predictors of TSP-related cardiac tamponade (TRCT) for all patients undergoing left atrial ablation at our centre from 2016-2020. Methods: Patient and procedural variables were extracted retrospectively. Cases of cardiac tamponade were scrutinised to adjudicate TSP culpability. Adjusted multivariate […]

  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72